Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.64M
-
Number of holders
-
50
-
Total 13F shares, excl. options
-
32.7M
-
Shares change
-
-12.9M
-
Total reported value, excl. options
-
$9.06M
-
Value change
-
-$111M
-
Put/Call ratio
-
0
-
Number of buys
-
26
-
Number of sells
-
-54
-
Price
-
$0.28
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q2 2024
95 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2024.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 50 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.7M shares
.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (12.8M shares), CITADEL ADVISORS LLC (4.77M shares), BlackRock Inc. (2.83M shares), Samsara BioCapital, LLC (2.78M shares), VANGUARD GROUP INC (1.73M shares), Ikarian Capital, LLC (1.06M shares), Rosalind Advisors, Inc. (1.03M shares), ACADIAN ASSET MANAGEMENT LLC (986K shares), MORGAN STANLEY (812K shares), and GEODE CAPITAL MANAGEMENT, LLC (755K shares).
This table shows the top 50 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.